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Summary
Molecular profiling of cancer at the transcript level has become routine. Large-scale analysis of proteomic alterations
during cancer progression has been a more daunting task. Here, we employed high-throughput immunoblotting in order
to interrogate tissue extracts derived from prostate cancer. We identified 64 proteins that were altered in prostate cancer
relative to benign prostate and 156 additional proteins that were altered in metastatic disease. An integrative analysis of
this compendium of proteomic alterations and transcriptomic data was performed, revealing only 48%–64% concordance
between protein and transcript levels. Importantly, differential proteomic alterations between metastatic and clinically
localized prostate cancer that mapped concordantly to gene transcripts served as predictors of clinical outcome in pros-
tate cancer as well as other solid tumors.S I G N I F I C A N C E
Multiple molecular alterations occur during cancer development. To begin to understand these processes, we need to characterize
and integrate these components. The present study is an attempt to integrate such disparate data as RNA and protein expression.
We employed an immunoblot approach to characterize proteomic alterations in prostate cancer. This approach revealed over 100
proteomic alterations in prostate cancer progression, some of which may have the potential to be developed as biomarkers or
therapeutic targets. Furthermore, we were able to integrate these proteomic profiles with transcript data from expression profiling
data sets. We found that the proteins that were qualitatively concordant with gene expression could be used as a predictor of
clinical outcome. Thus, this approach revealed the presence of a “progression signature” in prostate tumors.Introduction
Prostate cancer is a highly prevalent disease in older men of
the Western world (Chan et al., 2004; Linton and Hamdy, 2003).
Unlike other cancers, more men die with prostate cancer than
from the disease (Albertsen et al., 1998; Johansson et al.,
1997). Deciphering the molecular networks that distinguish
progressive disease from nonprogressive disease will shed
light into the biology of aggressive prostate cancer as well as
lead to the identification of biomarkers that will aid in the selec-
tion of patients that should be treated (Kumar-Sinha and Chin-
naiyan, 2003). To begin to understand prostate cancer pro-
gression with a systems perspective, we need to characterize
and integrate the molecular components involved (Grubb et al.,
2003; Hood et al., 2004; Paweletz et al., 2001; Petricoin et al.,
2002). A number of groups have employed gene expression
microarrays to profile prostate cancer tissues (DhanasekaranCANCER CELL : NOVEMBER 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIEet al., 2001; Lapointe et al., 2004; LaTulippe et al., 2002; Luo
et al., 2001, 2002b; Magee et al., 2001; Singh et al., 2002;
Welsh et al., 2001; Yu et al., 2004) as well as other tumors
(Alizadeh et al., 2000; Golub et al., 1999; Hedenfalk et al., 2001;
Perou et al., 2000) at the transcriptome level, but much less
work has been done at the protein level. Proteins, as opposed
to nucleic acids, represent the functional effectors of cancer
progression and thus serve as therapeutic targets as well as
markers of disease.
In the present study, we utilized a high-throughput immu-
noblot approach to characterize proteomic alterations in hu-
man prostate cancer progression, focusing on the transition
from clinically localized prostate cancer to metastatic disease.
Using an integrative approach, we were able to analyze proteo-
mic profiles with mRNA transcript data from several laborato-
ries. Our analyses also indicated that the proteins that wereR INC. DOI 10.1016/j.ccr.2005.10.001 393
A R T I C L EFigure 1. High-throughput immunoblot analysis to define proteomic alterations in prostate cancer progression
A: A flowchart of the general methodology employed to profile proteomic alterations in tissue extracts. Pooled tissue extracts (n = 5 each) from clinically
localized prostate cancer, hormone-refractory metastatic prostate cancer, and benign prostate tissues were separated on preparative SDS-PAGE gels
and transferred to PVDF membranes. The membranes were incubated with commercial antibodies using a miniblotter system. PCA, clinically localized
prostate cancer; MET, metastatic prostate cancer.394 CANCER CELL : NOVEMBER 2005
A R T I C L Ein situ technique such as evaluation by immunohistochemistry
B: Representative high-throughput immunoblots performed for pooled benign, clinically localized prostate cancer, and metastatic prostate cancer tissues.
Each lane represents analysis of an individual protein. Three representative blots are displayed for each tissue extract. Selected proteins altered in prostate
cancer progression are highlighted. MW, molecular weight. See the Supplemental Data for complete data set.
analyzed were unchanged in the context of prostate cancerqualitatively concordant with gene expression could be used
to define a multiplex gene predictor of clinical outcome.
Results and discussion
In order to derive a first approximation of the prostate cancer
proteome, we employed high-throughput immunoblot analysis.
This method, while not feasible for use on many individual
samples, allowed us to screen pooled tissue extracts for quali-
tative levels of hundreds of proteins (and posttranslational
modifications) using commercially available antibodies. The
basic approach is illustrated in Figure 1A. Extracts from five
tissue specimens of benign prostate, clinically localized pros-
tate cancer, and metastatic prostate cancer from distinct pa-
tients were pooled. Each of the three pools of tissue extracts
were run on preparative SDS-PAGE gels, transferred to PVDF,
and incubated with different antibodies using a miniblot appa-
ratus. Figure 1B displays representative data using the high-
throughput immunoblot approach. Known proteomic alterations
in prostate cancer progression such as EZH2 (Varambally et
al., 2002) and AMACR (Jiang et al., 2001; Luo et al., 2002a;
Rubin et al., 2002) are highlighted in red, while novel associa-
tions such as GSK-3β and IRAK1 are highlighted in green. To
further increase the number of proteins analyzed, we used an
analogous high-throughput immunoblot methodology provided
by commercial services (see Experimental Procedures). Thus,
in total we assessed 1484 antibodies against 1354 distinct pro-
teins or posttranslational modifications. Of these antibodies,
521 detected a band of the expected molecular weight in at
least one of the pooled extracts. Antibodies that did not detect
the correct molecular weight protein product may represent
lack of antibody sensitivity (or poor quality antibody) or ab-
sence of protein expression in prostate tissues.
To validate the proteomic alterations identified by this screen
in individual tissue extracts (as opposed to pooled extracts),
we analyzed 86 proteins and two posttranslational modifica-
tions by conventional immunoblot analysis using four to five
tissue extracts per class (see Figure S1). As with most gene
expression studies done in prostate, our proteomic screen em-
ployed grossly dissected tumor specimens. Thus, the proteo-
mic alterations that we detected could be due to differences in
the stromal-epithelial ratio of the tissues in addition to actual
alterations in the epithelial cells. In order to evaluate the pro-
teomic alterations in situ, we employed high-density tissue
microarrays (Kononen et al., 1998). As only a subset of the
identified proteins have antibodies that are compatible with im-
munohistochemical analysis, a single tissue microarray con-
taining 216 specimens from 51 cases was stained using 20 of
these IHC-compatible antibodies. Representative tissue micro-
array elements are shown in Figure 2A. Each tissue microarray
element was evaluated by a pathologist and scored for staining
(scale of 1 to 4) as per cell type considered (e.g., epithelial,
stromal, etc. . . .). Details of cell compartments used as the
readout for each element are shown in Table S11. Using anCANCER CELL : NOVEMBER 2005allowed us to distinguish stromally expressed versus epitheli-
ally expressed proteins. In general, proteins that demonstrated
a decrease in expression in the metastatic tumors most often
were stromally expressed proteins. As the amount of stroma
per unit area decreased with tumor progression, metastatic
samples demonstrated a parallel significant decrease in protein
expression of paxillin and ABP-280, among others (see Table
S11). In order to visualize and cluster the tissue microarray
data (Nielsen et al., 2003), the qualitative evaluations were nor-
malized (see Experimental Procedures). Similar to gene expres-
sion analyses (Eisen et al., 1998; Perou et al., 2000), unsuper-
vised hierarchical clustering of the data revealed that the in
situ protein levels could be used to accurately classify prostate
samples as benign, clinically localized prostate cancer, or met-
astatic disease (Figure 2B).
This high-throughput immunoblotting of prostate extracts
led to the identification of several known and previously un-
known proteomic alterations in prostate cancer. For example,
previous studies have shown that the antiapoptosis protein
XIAP (Krajewska et al., 2003), the racemase AMACR (Jiang et
al., 2001; Luo et al., 2002a; Rubin et al., 2002), and the poly-
comb group protein EZH2 (Varambally et al., 2002) are dysreg-
ulated in prostate cancer progression. Novel associations (in-
creases or decreases in protein expression) with prostate
cancer progression identified by this screen include the E2
ubiquitin ligase UBC9, the cytosolic phosphoprotein stathmin,
the death receptor DR3, and the Aurora-A kinase (STK15),
among others. Descriptions and potential functional context of
the various proteomic alterations identified by this screen are
found in the Supplemental Data.
Having amassed this compendium of proteomic alterations
in prostate cancer progression, we next examined the general
concordance with the prostate cancer transcriptome. To this
end, we developed an integrative model to incorporate qualita-
tive proteomic alterations as assessed by high-throughput im-
munoblotting (but applicable to other proteomic technologies),
with transcriptomic data derived from eight prostate cancer
gene expression studies (Figure 3). As both the genomic and
proteomic approaches involve analysis of grossly dissected tis-
sues, this facilitates molecular comparisons to be made. The
high-throughput immunoblot analysis of benign prostate, clini-
cally localized prostate cancer and metastatic disease yielded
521 proteins of the expected molecular weight. Immunoreac-
tive bands in each of the three tissue extracts were assessed,
and comparisons were made between benign tissue and clini-
cally localized prostate cancer (Figure 3A) and between clinically
localized prostate cancer and metastatic disease (Figure 3B).
Qualified proteins that were overexpressed were coded red,
underexpressed proteins were coded blue, and unchanged
proteins were coded white. Based on this analysis, 64 proteins
were dysregulated in clinically localized prostate cancer rela-
tive to benign prostate tissue, while 156 proteins were dysregu-
lated between metastatic disease relative to clinically localized
prostate cancer. As might be expected, most of the proteins395
A R T I C L EFigure 2. Tissue microarray analyses of protein markers deregulated in prostate cancer progression
A: Selected images of tissue microarray elements representing immunohistochemical analysis of proteins altered in prostate cancer progression. Relative
levels of proteins as assessed by blinded pathology analysis of tissue microarrays (n = 216 specimens) are provided to the right. See the Supplemental
Data for details regarding 20 markers evaluated by immunohistochemistry.
B: Cluster analysis of 20 proteins dysregulated in prostate cancer progression evaluated for in situ protein levels by tissue microarrays. Unsupervised
hierarchical clustering of protein levels (columns) and samples (rows) was performed, and a heat map was generated. Red color represents high protein
levels, while black refers to intermediate levels, and green represents low or absent protein levels.progression (i.e., 87.7% [457/521] of the proteins were un-
changed between clinically localized prostate cancer and be-
nign and 70.1% [365/521] of the proteins were unchanged be-
tween clinically localized and metastatic disease).
The set of qualifiable proteins (n = 521) was then mapped to
the NCBI LocusLink and UniGene databases to identify each
corresponding gene. Data for mRNA were extracted for these396genes using eight publicly available prostate cancer gene ex-
pression data sets (see Experimental Procedures). Over 90%
of the genes were represented in at least one microarray study,
allowing for integrative analysis to be performed. All eight of
the prostate profiling studies made a comparison between clin-
ically localized prostate cancer and benign tissue, while only
four of these studies made a comparison between clinicallyCANCER CELL : NOVEMBER 2005
A R T I C L Elocalized disease and metastatic disease. Genes that could
only be found in one-fourth of studies or less were excluded,
leading to 481 genes involved in the former comparison and
492 involved in the latter comparison. Since we assessed over-
and underexpressed genes separately, a one-sided Welch’s t
test was conducted per each gene per each profiling study
(see Experimental Procedures). As with the proteomic ap-
proach, comparisons between benign and clinically localized
prostate cancer (Figure 3A) and localized disease and meta-
static disease (Figure 3B) were made. If an mRNA transcript
was significantly overexpressed in a particular study, it was
coded red; underexpressed transcripts were coded blue, and
white was used for unchanged transcripts.
Figure 3 presents an integrative analysis of proteomic data
with gene expression metadata in prostate cancer progression.
An mRNA transcript alteration was considered “concordant”
with a proteomic alteration if a majority of the microarray profil-
ing studies (at least 50%) showed the same qualitative dif-
ferential (increased, decreased, or unchanged) as the high-
throughput immunoblot approach. According to these criteria,
289 (60.1%) out of 481 mRNA transcripts were concordant
with protein levels in clinically localized prostate cancer relative
to benign prostate tissue. Similarly, 291 (59.1%) out of 492
mRNA transcripts were concordant with protein levels in meta-
static prostate cancer relative to clinically localized disease.
Out of the 156 proteomic alterations identified between meta-
static and localized prostate cancer, 50 were concordant with
mRNA transcript and 90 were discordant with mRNA tran-
script, while the remaining alterations did not have mRNA mea-
surements to map to (Figures 3B and 3C). Thus, similar to
studies done in yeast (Griffin et al., 2002; Washburn et al.,
2003), bacteria (Baliga et al., 2002), and cell lines (Tian et al.,
2004), there was only weak concordance between protein and
mRNA levels in prostate cancer progression.
To further explore the poor concordance we observed be-
tween protein and metadata from transcriptomic analyses, we
profiled the pooled samples as well as the individual samples
that comprised the pools on Affymetrix HG-U133 plus 2 micro-
arrays. The same integrative analysis was carried out to exam-
ine the concordant relationship between the protein alterations
observed in the pooled tissues by immunoblotting and tran-
script alterations observed in the corresponding pooled and
individual tissues. The individual samples were included in or-
der to calculate statistical significance for transcript alterations.
Similar or even lower concordance was observed between pro-
tein and transcript (61.0% concordance in clinically localized
prostate cancer relative to benign prostate tissue, and 48.2%
for metastatic prostate cancer relative to clinically localized
disease; Figure 4A; Figure S4A).
We also investigated the protein and mRNA concordance in
individual samples. We focused on the 86 proteins identified
as outliers in the larger high-throughput screen (see Figure S1).
The immunoblot intensities were semiquantitated, and correla-
tion coefficients were calculated for each protein (see Experi-
mental Procedures). We found that a total 55 out of 86 proteins
were observed to a have a positive correlation with mRNA,
which led to 64.0% concordance between proteins and tran-
scripts (Figure 4B). On subclassification, we observed a con-
cordance of 54.7% and 66.3% in case of localized prostate
cancer relative to benign prostate tissues and the metastatic
disease relative to localized prostate cancer, respectively.CANCER CELL : NOVEMBER 2005This proteomic screen identified proteins that are altered
from benign prostate to clinically localized prostate cancer and
a distinct set of alterations between clinically localized disease
to metastatic disease. Since our group is interested in the tran-
sition from clinically localized to metastatic disease, we next
focused on this comparison. As the metastatic tissues ana-
lyzed in this study are androgen independent (Shah et al.,
2004), and by contrast the clinically localized tumors are gen-
erally androgen dependent, we evaluated whether there was
an enrichment of androgen-regulated proteomic alterations
discovered by our screening. Androgen-regulated genes (ARGs)
are essential for the normal development of the prostate as
well as the pathogenesis of prostate cancer (Culig et al., 1998;
Koivisto et al., 1998; Mooradian et al., 1987). Pertinent to this
analysis, Velasco et al. developed a meta-analysis of ARGs
that represents a cross-comparison of four gene expression
(DePrimo et al., 2002; Nelson et al., 2002; Segawa et al., 2002;
Velasco et al., 2004) and two SAGE data sets (Waghray et al.,
2001; Xu et al., 2001). ARGs were then defined as a union of
these six data sets, all of which represented functional induc-
tion of mRNA transcript by androgen in vitro. Interestingly, 27
out of the 150 protein alterations (exclusive of posttranslational
modifications) that we identified as being differential between
metastatic and clinically localized disease were designated as
androgen regulated by the Velasco et al. (2004) ARG compen-
dium (see Supplemental Data). To demonstrate that this finding
is statistically significant, we selected random sets of 150
genes from the Yu et al. (2004) or the Glinsky et al. (2004) pros-
tate cancer profiling studies and found that the chance of se-
lecting 27 ARGs was minimal (p < 0.001 for both the Yu et al.
and Glinsky et al. data). Thus, androgen-regulated proteins are
significantly enriched in the differential comparison between
androgen-dependent and independent prostate cancer.
While examining concordant proteomic alterations, interest-
ingly, we found that EZH2, a polycomb group protein that we
and others have previously characterized as being overex-
pressed in aggressive prostate and breast cancer (Kleer et al.,
2003; Varambally et al., 2002) was one of the 50 proteins iden-
tified as being concordantly overexpressed in metastatic tis-
sues at the mRNA and protein level (Figures 3B and 3C). As
EZH2 was a member of this 50-gene concordant signature, we
hypothesized that proteomic alterations that distinguish meta-
static prostate cancer from clinically localized disease may
serve as a multiplex signature of prostate cancer progression
when applied to clinically localized disease (i.e., “more aggres-
sive” genes would be expressed in progressive prostate can-
cer). While antibodies have yet to be developed to test all of
these proteomic alterations in situ by immunohistochemistry,
we postulated that mRNA transcript levels could be used in-
stead due to their concordance with protein levels in this signa-
ture. To test this hypothesis, we selected prostate cancer gene
expression data sets that monitored over 85% of the genes
in the concordant genomic/proteomic signature and included
biochemical recurrence information (time to PSA recurrence),
as well as reported on at least 50 clinically localized speci-
mens. According to Dobbin and Simon (2005), the number of
samples required for developing prognostic markers was ap-
proximately 51 or above for a general human gene expression
data set with the variance of a gene over samples as 0.5, type
I error as 0.001, and type II error as 0.05. Thus, we chose n =
50 as our minimal sample size requirement in this analysis.397
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A R T I C L Eset. Table 1 shows that the concordant signature predicted re-
Figure 3. Integrative analysis of proteomic and transcriptomic metadata in prostate cancer progression
A: Color map of integrative analysis relating protein alterations to gene expression in clinically localized prostate cancer relative to benign prostate tissue.
For gene expression meta-analysis (transcript analysis), the first author of each prostate cancer gene expression study is indicated in columns, while
individual genes are represented as rows. Red color indicates significantly increased expression at the p = 0.05 threshold level for prostate cancer relative
to benign tissue, while blue indicates downregulation at the same threshold, and white indicates unchanged expression. Protein levels (protein) in pooled
clinically localized prostate cancer extracts (as described in Figure 1) were qualified by high-throughput immunoblot analysis as overexpressed (red),
underexpressed (blue), or unchanged (white) and mapped to the corresponding mRNA transcript. Proteins that were not expressed (or corresponding
antibodies that did not produce an immunoreactive band of the correct molecular weight) or proteins whose corresponding mRNA transcript level was
not present in over one-fourth of the profiling studies were excluded from the integrative analysis. Proteomic alterations in prostate cancer that were
concordant or discordant with the meta-analysis of gene expression were expanded to the right. See the Experimental Procedures and Supplemental
Data for details and complete data set.
B: As in A, except the integrative analysis was carried out between metastatic prostate cancer relative to clinically localized prostate cancer.
C: Conventional immunoblot validation of selected proteins differentially expressed between metastatic prostate cancer and clinically localized prostate
cancer. Individual tissue extracts from three to four benign, five clinically localized prostate cancer, and five metastatic prostate cancer samples are
shown. Validation of additional markers that distinguish clinically localized prostate cancer and benign tissue can be found in the Supplemental Data.
performance in most of the studies, especially when employingThe prostate cancer gene expression data sets that fulfilled
these criteria were carried out by Yu et al. (2004) and Glinsky
et al. (2004), both of which represent Affymetrix oligonucleotide
data sets and each of which measured at least 44 out of the
50 genes in the concordant signature. Although the Singh et
al. and LaPointe et al. studies reported over 50 samples in their
studies, the number of samples for which we have available
follow-up information was less than 30 (29 and 20 samples for
the LaPointe and Singh data sets, respectively). In addition, the
average follow-up time for the samples in LaPointe study was
only 10.7 months. Thus, we excluded both data sets in the
analysis. We then chose to build our prediction models with
the Yu et al. data set and test the performance on the Glinsky
et al. data set. Utilizing an approach described earlier (Rama-
swamy et al., 2003), unsupervised hierarchical clustering in the
space of this 44-gene concordant signature resulted in two
main clusters of individuals in the Yu et al. study (Figure 5A).
Kaplan-Meier (KM) survival analysis of the clusters indicated
that the two groups of individuals are significantly different
based on time to recurrence status (p = 0.035; Figure 5A). No-
tably, when we use the 90 discordant genes (mRNA transcripts
that are not qualitatively concordant with protein levels) we
found that these signatures did not generate a clinical outcome
distinction (p = 0.238; Supplemental Data). Moreover, by per-
mutation test, we also observed that random sets of 44 genes
did not generate such prognostic distinctions (see Experimen-
tal Procedures), indicating that our concordant signature was
not likely due to chance. To assess the validity of this concor-
dant signature, we utilized the Glinsky et al. study as an inde-
pendent test set (Figure 5B). Each of the samples in the Glinsky
data set was classified as high- or low-risk based on a k-near-
est neighbor (k-NN) model developed using the Yu et al. study
as a training set (k = 3). Based on the class predictions derived
from the concordant signature, KM survival analysis revealed a
significant difference in survival based on the risk stratification
(p = 0.001; Figure 5B). As expected, this was not the case with
the discordant signature when applied to the Glinsky et al.
sample set (p = 0.556; Supplemental Data). A similar result was
observed when a predictive model built on the Glinsky et al.
data was applied to the Yu et al. data (p < 0.001 and p = 0.02
for the Glinsky et al. and Yu et al. data, respectively). We then
carried out multivariate Cox proportional hazards regression
analysis of the risk of recurrence on the Glinsky et al. validationCANCER CELL : NOVEMBER 2005currence independently of the other clinical parameters such
as surgical margin status, Gleason sum, and preoperative PSA.
With an overall hazard ratio of 3.66 (95% CI: 1.36–7.02; p <
0.001), it was by far the strongest predictor of prostate cancer
recurrence in the model.
Next, we sought to refine the concordant signature of pros-
tate cancer progression by reducing the number of genes re-
quired. By using the Yu et al. study as a training set, we ranked
the 44 concordant genes by a univariate Cox model. The same
clustering procedure was employed to identify two clusters
based on the top number of genes ranging from a minimum of
5 to a maximum of 44. Based on this iterative analysis, we
identified nine genes that demarcated two main clusters that
differed most significantly by KM survival analysis (Figure 5A;
Experimental Procedures). The Glinsky et al. study was again
used as an independent validation set confirming that the 9-gene
concordant signature identified two groups of individuals that
differed significantly based on recurrence (Figure 5B; Figure
S5). Taken together, this integrative analysis suggests that mRNA
transcripts that correlate with protein levels in metastatic pros-
tate cancer can be used as gene predictors of progression in
clinically localized disease.
Next, we sought to explore the generality of the concordant
progression signature in other solid tumors. We identified four
tumor profiling data sets from the Oncomine compendium
(Rhodes et al., 2004) that fulfilled the same criteria that we
used in the prostate cancer analyses (see above). In 95 primary
breast adenocarcinomas (van ’t Veer et al., 2002), tumors bear-
ing the 50-gene concordant progression signature were more
likely to progress to metastasis than those lacking this signa-
ture (p = 0.0025; Supplemental Data). We observed a similar
result in 80 primary breast infiltrating ductal carcinomas (Huang
et al., 2003) (p = 0.002; Figure 5C). Moreover, this result was
also observed in a series of 84 primary lung adenocarcinomas
(Bhattacharjee et al., 2001) (p = 0.03; Figure 5C) and 56 glio-
mas (Freije et al., 2004) (p = 0.01; Figure 5C). Furthermore, we
used two common gene expression prediction models (diago-
nal linear discriminant analysis and k-NN analysis) and con-
ducted direct comparisons of the performances of the pro-
gression signature and the “study-specific” signature in each
individual study where such a specific signature was available
(see Table S12). The result indicated that the progression sig-
nature was able to retrieve similar or even superior prediction399
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Figure 4. Integrative genomic and proteomic analysis of pooled and individual prostate tissue extracts
A: Color maps of integrative analyses relating protein alterations observed in pooled tissues by immunoblotting and transcript alterations observed in the
pooled and individual tissues by gene expression analyses. Please refer to Figure 3A for color scheme.
B: Color maps depicting integrative genomic and proteomic analysis of individual prostate tissue samples. Proteins in each tissue extract were assessed
based on intensities derived from conventional immunoblot analysis. We focused on 86 distinct proteins identified as differential based on high-throughput
analysis (Figures 3 and 4A). Transcriptomic profiles from the same samples were derived from Affymetrix microarrays. The immunoblot intensities were
semiquantitated, and a correlation was calculated for each protein. Concordance was defined based on positive correlation between proteins and
transcripts (see the Experimental Procedures and Supplemental Experimental Procedures).
examination of the frozen sections of each tissue block, specimens werethe k-NN prediction model. This is remarkable, as this signa-
ture was derived exclusively from prostate samples but had
utility not only in prostate cancer data sets but also in breast
cancer, lung cancer, and glioma data sets. Again, this suggests
that there is likely biology inherent in the integrated predictor.
Of note, we found that the smaller 9-gene model was only ef-
fective in discriminating prognostic classes in the Freije et al.
glioma study (p = 0.016) but not in the other solid tumor data
sets (Supplemental Data). This suggests that the 9-gene model
may be relatively specific for prostate cancer while the 50-gene
model has more universal applicability. Taken together, our ob-
servations suggest that the progression proteomic/genomic
signature identified by the integrative analysis of metastatic
prostate cancer may have utility in the prognostication of clini-
cally localized solid tumors in general. Biologically, this sug-
gests that aggressive tumors of different tissue origin begin to
share the molecular machinery of a dedifferentiated state.
While these proteomic alterations have potential to serve as
a multiplex biomarker of cancer aggressiveness, they may also
shed light into the biology of neoplastic progression. As pro-
teins, rather than RNA transcripts, are the primary effectors
of the cell, they play the central and most distal role in the
functional pathways to cancer. Interestingly, EZH2, which we
previously have shown to have a role in prostate cancer pro-
gression (Varambally et al., 2002), is a member of this concor-
dant genomic/proteomic signature, suggesting that other mem-
bers of this signature may have utility as biomarkers as well as
could have a role in the biology of progression. For example,
this screen identified Aurora-A kinase (STK15) as being overex-
pressed in metastatic prostate cancer as well as being a mem-
ber of the 50-gene concordant signature. This serine-threonine
kinase has been shown to be amplified in a number of human
cancers (Jeng et al., 2004; Neben et al., 2004), play a key role
in G2/M cell cycle progression (Hirota et al., 2003), and inhibit
p53 (Katayama et al., 2004), among other functions. Another
candidate cancer regulatory molecule in the 50-gene con-
cordant signature was KRIP1 (KAP-1), which is known to re-
press transcription via binding the methyltransferase SETDB1
(Schultz et al., 2002). Refer to the Supplemental Data for addi-
tional markers identified by this screen as well as pathway en-
richment analysis.
In this study, we initially used a pooling strategy to perform
high-throughput immunoblot analysis. While it would be more
ideal to involve replicate protein measurements across multiple
prostate tissues and then make comparisons to mRNA, the dif-
ficulty in monitoring thousands of antibodies on many indi-
vidual samples and the cost of running multiple samples
across thousands of antibodies required us to adopt the pool-
ing approach. Further, analyses of concordance with mRNACANCER CELL : NOVEMBER 2005firmed the general feasibility of this strategy. We also noticed
that there were recognized problems with annotations for
microarrays. A recent study (Mecham et al., 2004) reported that
up to 50% Affymetrix probes do not have a matching sequence
in the Reference Sequence database (Refseq), questioning the
reliability of such probes. As this study represents an initial
foray in the area of integrative analyses, we used basic gene
identifier-based matching for cross-platform annotations. An-
other potential limitation in the present study is that many im-
munoblots exhibit reactivity at multiple sizes potentially repre-
senting multiple protein isoforms. Thus, measuring the protein
intensity for one “expected” band may not be adequate for
determining a correlation with transcripts. However, most of
the reported changes here are the result of alterations in the
reported or predicted molecular weight isoform. In future
studies, we will investigate the various isoforms and proteolyti-
cally cleaved products.
Taken together, the present study provides a general frame-
work for the integrative analysis of proteomic and transcripto-
mic data from human tumors (Figure 6). Proteomic profiling of
prostate cancer progression identified over 100 altered pro-
teins in the transition from clinically localized to metastatic dis-
ease (a significant fraction of which were androgen regulated).
While this approach was useful to integrate high-throughput
immunoblot data, the general paradigm can also be applied to
mass spectrometry or protein microarray-based technologies
as they mature in the future. Differential proteins were then
mapped to mRNA transcript levels to assess mRNA/protein
concordance levels in a human disease state. Importantly,
gene expression alterations that matched protein alterations
qualitatively could be used as predictors of prostate cancer
progression in clinically confined disease. Thus, this would
suggest that clinically aggressive prostate cancer bears a “sig-
nature” set of genes/proteins that is characteristic of meta-
static disease. The observation that the concordant proteomic/
genomic signature can be applied to other solid tumors sug-
gests commonalities in the undifferentiated state of advanced
tumors.
Experimental procedures
High-throughput immunoblot analysis
Tissues utilized were from the radical prostatectomy series at the University
of Michigan and from the Rapid Autopsy Program, which are both part of
University of Michigan Prostate Cancer Specialized Program of Research
Excellence (SPORE) Tissue Core. Institutional Review Board approval was
obtained to procure and analyze the tissues used in this study. To develop
the tissue extract pools, the following frozen tissue blocks were identified:
five each of benign prostate tissues, clinically localized prostate cancer,
and hormone-refractory metastatic tissues (Shah et al., 2004). Based on401
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Figure 5. Proteomic alterations in metastatic prostate cancer identify gene predictors of cancer aggressiveness
A: A concordant 44 (out of 50)-gene predictor was developed based on proteomic alterations that were concordant with gene expression (Figure 3B)
and subsequently evaluated for prognostic utility on a prostate cancer gene expression data set (Yu et al.). Hierarchical clustering of the tumor samples
(columns) and genes (rows) is provided (left panel). Red indicates high relative levels of gene expression, while green represents low relative levels of
gene expression. Horizontal bars above the heat maps indicate the recurrence status of each patient (black box, biochemical or tumor recurrence; white
box, recurrence-free). Patients were categorized into two major clusters defined by the 44-gene signature. The prediction model was further refined to a
9-gene signature (see Supplemental Data). Kaplan-Meier survival analysis based on the groups defined by the 44-gene concordant cluster (middle panel)
and the 9-gene concordant cluster (right panel). Similar analyses performed with discordant genes can be found in the Supplemental Data.
B: The concordant 44-gene predictor and the refined concordant 9-gene predictor were evaluated in an independent prostate cancer profiling data
set. Each sample was assigned to a low-risk or high-risk group by k-nearest neighbor classification using cluster-defined low-/high-risk groups in the Yu et
al. training data set (left panel; Supplemental Experimental Procedures). Kaplan-Meier plot of the predicted high-/low-risk groups in the space of the
concordant 44 genes (middle panel) or the concordant 9 genes (right panel).
C: Same as A, except the concordant predictor was evaluated in other solid tumors. Huang et al. (2003) breast adenocarcinoma (left panel), Freije et al.
(2004) glioma (middle panel), and Bhattacharjee et al. (2001) lung adenocarcinoma (right). Analysis using the van ’t Veer breast cancer profiling data
set (van ’t Veer et al., 2002) can be found in the Supplemental Data.
samples based on the 44 concordant mRNA transcripts that were qualita-Table 1. Multivariable proportional hazards analysis of the risk of recurrence as a first event on the Glinsky et al. validation set
Variable Hazard ratio (95% CI) p value
High-risk signature (versus low-risk signature) 3.66 (1.77–7.59) <0.001
PSA 1.04 (1.00–1.09) 0.043
Gleason sum score: score > 7 (versus score % 7) 1.73 (0.79–3.76) 0.17
Tumor stage: stage T2 (versus stage T1) 0.85 (0.42–1.75) 0.67
Age 1.06 (1.00–1.13) 0.06
Surgical margins: positive (versus negative) 2.18 (0.92–5.18) 0.08grossly dissected maintaining at least 90% of the tissue of interest. Total
proteins were extracted from each tissue by homogenizing samples in boil-
ing lysis buffer. One hundred micrograms of protein from each tissue extract
pool was boiled in sample buffer and subjected to 4%–15% preparative
SDS-PAGE and transferred to PVDF and probed with different antibodies.
To supplement the number of proteins analyzed, the same extracts were
analyzed using two commercial service providers, BD Biosciences and Ki-
nexus. Detailed methods for high-throughput immunoblot analyses are pro-
vided in the Supplemental Data. Validation immunoblots for selected pro-
teins in different functional classes were carried out using 4%–15% linear
gradient SDS-PAGE for protein separation. The signal intensities were semi-
quantitated using Scion Image software.
Microarray analyses
Total RNA from the individual and pooled samples were analyzed on Affy-
metrix U133 2.0 Plus arrays by the University of Michigan Comprehensive
Cancer Center Affymetrix Core. The amount and integrity of RNA were ana-
lyzed by spectrophotometry and the Agilent Bioanalyzer (Agilent Technol-
ogies). Biotin-labeled cRNA synthesis, hybridization, washing, staining, and
scanning were done following the manufacturer’s protocols (Affymetrix). All
RNA samples and arrays met standard quality control metrics. The expres-
sion profiling data were deposited into GEO under accession number
GSE3325 (available at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE3325).
Tissue microarray analysis
A prostate cancer progression tissue microarray analysis composed of be-
nign prostate tissue, clinically localized prostate cancer, and hormone-
refractory metastatic prostate cancer was developed. These cases came
from well-fixed radical prostatectomy specimens as described previously
(Rubin et al., 2002). Protein expression was determined using a validated
scoring method (Dhanasekaran et al., 2001; Rubin et al., 2002; Varambally
et al., 2002) where staining was evaluated for intensity and the percentage
of cells staining positive. Detailed methods for tissue microarray analyses
can be found in the Supplemental Data.
Integrative molecular analysis
To map the antibodies and their respective protein targets, we retrieved theCANCER CELL : NOVEMBER 2005To complement protein levels, transcriptome data were assembled from
eight publicly available prostate cancer gene expression data sets (Dhana-
sekaran et al., 2001; Lapointe et al., 2004; LaTulippe et al., 2002; Luo et al.,
2001, 2002b; Singh et al., 2002; Welsh et al., 2001; Yu et al., 2004), and
each probe was mapped to Unigene Build #173 (Table S3). Expression val-
ues from multiple clones or probe sets mapping to the same Unigene Clus-
ter ID were averaged. Each gene in each study was normalized across sam-
ples so that the mean equaled zero and the standard deviation equaled
1. Missing data were imputed by the k-NN (k = 5) imputation approach
(Troyanskaya et al., 2001).
Eight prostate cancer profiling studies were included in the analysis of
clinically localized prostate cancer relative to benign prostate tissue, while
only four studies were included in the analysis of metastatic prostate cancer
versus localized prostate cancer due to the availability of metastatic sam-
ples in those studies (Table S4). Detailed methods for integrative molecular
analysis can be found in the Supplemental Data.
Integrative genomic and proteomic analysis of individual
prostate cancer samples
We carried out profiling of mRNA expression analysis in 13 of the 14 individ-
ual samples used for the individual protein measurements (one was ex-
cluded due to an insufficient amount of tissue). We examined the concor-
dance between proteins and transcripts for individual samples, focusing on
the 86 proteins identified as outliers in the larger high-throughput screen
(see Figure S1). The immunoblot intensities were semiquantitated using
Scion Image software, and the Spearman’s rank correlation was calculated
for each protein. An mRNA transcript alteration was considered “concor-
dant” with a proteomic alteration if a positive correlation was found.
Clinical outcomes analysis
Six different cancer profiling studies (Bhattacharjee et al., 2001; Freije et al.,
2004; Glinsky et al., 2004; Huang et al., 2003; van ’t Veer et al., 2002; Yu et
al., 2004) were used for evaluation of prognostic value of these concordant
genes. Detailed study information is shown in Table S5, and gene expres-
sion data utilized for the study are described in Table S6. Average linkage
hierarchical clustering using an uncentered correlation similarity metric was
used to identify two main clusters of clinically localized prostate cancer403
A R T I C L EFigure 6. Integrative molecular analysis of cancer to identify gene predictors of clinical outcome
Proteomic profiles comparing metastatic prostate cancer to clinically localized prostate cancer were used to identify a composite gene predictor of
clinical outcome in localized disease. This integrated proteomic-transcriptomic signature represents a prostate cancer progression signature and can be
extended to other solid tumors.tively concordant with protein expression in the Yu et al. (2004) study (only
44 out of 50 of the concordant signature were assessed on these arrays).
To validate the prognostic association of the 44-gene concordant signa-
ture, an independent (clinically localized) prostate cancer gene expression
data set from Glinsky et al. (Glinsky et al., 2004) was used. The Yu et al.
clustering functioned as the “training set” to define high-/low-risk groups.
This “progression” signature was then refined by reducing the number of
genes involved. By using Yu et al. study as a training set, we ranked the
concordant genes by univariate Cox model. The generality of this “pro-
gression” signature was evaluated by using other solid tumor data sets. The
signature was applied to two breast cancer (Huang et al., 2003; van ’t Veer
et al., 2002), one lung cancer (Bhattacharjee et al., 2001), and one glioma
(Freije et al., 2004) gene expression study. Detailed methods for clinical
outcomes analysis can be found in the Supplemental Data.
Multivariable analysis
We used a Cox proportional hazards regression model to carry out the mul-
tivariate analysis. The dichotomized values of the concordant “progression”
signature, preoperative PSA, Gleason sum score from prostatectomy speci-
mens, preoperative clinical stage, age, and status of surgical margins were404included as covariates. The calculation was performed with the R 2.0 statis-
tical package.
Pathway analysis
To better understand the biological pathways at work in the concordant and
discordant signature, we searched for association of these genes with gene
sets defined by Gene Ontology and Transfac analysis (Rhodes et al., 2005).
The overlap of the signature with each gene set was counted, and the
significance of the overlap was evaluated with Fisher’s exact test.
Supplemental data
The Supplemental Data include supplemental results, discussion, and ex-
perimental procedures; six supplemental figures; and 12 supplemental ta-
bles. The Supplemental Data can be found with this article online at http://
www.cancercell.org/cgi/content/full/8/5/393/DC1/.
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